Metabotropic glutamate receptors (mGluRs) regulate noxious stimulus-induced glutamate release in the spinal cord dorsal horn of rats with neuropathic and inflammatory pain.
In rats with persistent pain, spinal group I metabotropic glutamate receptor (mGluR) activity has been shown to be pronociceptive, whereas spinal group II/III activity is anti-nociceptive. In brain, group I mGluR activity produces positive feedback effects on glutamate release, whereas group II/III activity produces negative feedback effects. It is unknown whether the nociceptive versus anti-nociceptive effects of spinal group I versus group II/III mGluR activity depend on differential regulation of spinal glutamate release. Here, we used behavioral nociceptive testing and in vivo microdialysis to assess the effect of intrathecal treatment with group I mGluR antagonists [cyclopropan[b] chromen-1a-carboxylate, (CPCCOEt), 2-methyl-6-(phenylethynyl) pyridine (MPEP)] or groups II [aminopyrrolidine-2R,4R-dicarboxylate (APDC)] and III [l-2-amino-4-phosphonobutyrate (l-AP4)] mGluR agonists or vehicle, on nociception and noxious stimulus-induced increases in glutamate release in the spinal cord dorsal horn of rats with a chronic constriction injury (CCI) of the sciatic nerve or hind paw injection of complete Freund's adjuvant (CFA). None of the treatments significantly influenced basal spinal glutamate concentrations in either CCI or CFA rats. In CCI rats, formalin-induced nociception and increases in spinal glutamate concentrations were significantly attenuated by pre-treatment with CPCCOEt, MPEP, APDC, or l-AP4. In CFA rats, capsaicin-induced increases in nociception and spinal glutamate concentrations were significantly attenuated by pre-treatment with CPCCOEt, MPEP, or APDC, but not l-AP4. This study demonstrates that group I antagonists and group II/III mGluR agonists attenuated the enhanced nociception and noxious stimulus-induced glutamate release in spinal cord dorsal horn of CCI and/or CFA rats in vivo, and suggests a possible mechanism for their anti-hyperalgesic effects.
Kumar
Naresh
N
Department of Anesthesia, McGill University, Montreal, Quebec, Canada H3G 1Y6.
Laferriere
Andre
A
Yu
Jonathan S C
JS
Poon
Tanya
T
Coderre
Terence J
TJ
D000818:Animals; D002211:Capsaicin / Q000494:pharmacology; D018698:Glutamic Acid / Q000378:metabolism*; D007249:Inflammation / Q000378:metabolism; D008297:Male; D010146:Pain / Q000378:metabolism*; D010147:Pain Measurement; D010523:Peripheral Nervous System Diseases / Q000378:metabolism*; D020671:Posterior Horn Cells / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D020318:Rats, Long-Evans; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*
D018094:Receptors, Metabotropic Glutamate; D018698:Glutamic Acid; D002211:Capsaicin
Neurosci Lett. 2004 May 6;361(1-3):220-4
15135933
Anesth Analg. 2007 Apr;104(4):936-43
17377110
Neurosci Lett. 2002 Jul 26;327(3):198-202
12113911
J Neurophysiol. 2004 Jan;91(1):13-24
13679408
Eur J Pharmacol. 2007 Sep 24;571(1):8-16
17597604
J Pharmacol Exp Ther. 2002 Jan;300(1):149-56
11752110
Neuroreport. 1994 Dec 30;6(1):209-13
7703417
Pain. 2005 May;115(1-2):37-49
15836968
Pain. 1988 Apr;33(1):87-107
2837713
Neuroscience. 1998 Jan;82(2):591-602
9466463
Neurosci Lett. 1999 Mar 5;262(2):101-4
10203241
Neuropharmacology. 2005 Mar;48(3):325-32
15721164
Pain. 2001 Oct;94(1):59-63
11576745
Mol Pain. 2009 Sep 02;5:50
19725970
Eur J Pharmacol. 1998 Apr 24;347(2-3):165-72
9653877
Neuroreport. 1998 Oct 5;9(14):3219-22
9831454
Neuropharmacology. 2007 Feb;52(2):253-62
17113112
Eur J Pain. 2000;4(1):111-3
10833561
Neurosci Res. 1999 Jul;34(2):73-8
10498333
Br J Pharmacol. 2002 Mar;135(5):1255-62
11877334
Neuroreport. 2000 Sep 28;11(14):3067-70
11043525
Pain. 1996 Oct;67(2-3):345-54
8951928
Neuroscience. 2000;100(2):393-406
11008177
Neuropharmacology. 2001 Sep;41(4):523-7
11543773
Neurosci Lett. 1997 Jul 4;229(3):161-4
9237483
Brain Res Bull. 2009 May 29;79(3-4):219-23
19429193
Neuroscience. 2001;105(4):957-69
11530234
J Comp Neurol. 2000 Jul 3;422(3):464-87
10861520
Pharmacol Biochem Behav. 2002 Sep;73(2):419-27
12117597
Eur J Neurosci. 1997 Jul;9(7):1350-5
9240392
Life Sci. 2004 May 14;74(26):3235-44
15094324
J Neurochem. 2003 Dec;87(5):1204-12
14622100
Pharmacol Biochem Behav. 2002 Sep;73(2):411-8
12117596
Eur J Pharmacol. 1998 Apr 24;347(2-3):189-95
9653880
J Neurochem. 2005 Aug;94(4):1131-9
16092950
Neurosci Lett. 1995 Dec 29;202(1-2):85-8
8787837
Exp Brain Res. 2003 May;150(2):194-200
12669169
Annu Rev Neurosci. 1994;17:31-108
8210177
J Pharmacol Exp Ther. 2005 Jan;312(1):120-6
15375175
Mol Pharmacol. 2002 May;61(5):989-96
11961116
Neuropharmacology. 1995 Jan;34(1):1-26
7623957
J Comp Neurol. 2007 Dec 1;505(4):412-23
17912745
J Neurochem. 2010 Jan;112(1):162-72
19840219
Brain Res. 2001 Sep 14;913(1):18-26
11532243
Neuroreport. 2000 Jun 5;11(8):1631-5
10852214
Eur J Neurosci. 2007 Jul;26(2):312-22
17650109
Neuroreport. 1997 Aug 18;8(12):2695-9
9295103
Eur J Pharmacol. 2004 Dec 15;506(2):107-18
15588730
Anesth Analg. 2003 Aug;97(2):520-525
12873947
Neurosci Lett. 1992 Oct 12;145(2):141-4
1361220
Neuroscience. 1996 Apr;71(4):949-76
8684625
Pain. 1993 Apr;53(1):81-88
8316394
Pain. 2008 Jul;137(1):112-124
17900808
J Comp Neurol. 2001 Feb 19;430(4):448-57
11169479
Neuroreport. 2000 Nov 9;11(16):3611-4
11095529